University biotech spinout Rage lands $29 million Series A
Rage Biotech, a therapeutics startup tackling chronic inflammatory disease, has raised $29 million in a Series A. The round was led by IP Group Australia and super fund Hostplus, with support from existing investors including Monash Ventures. The funds will go towards first-in-human clinical trials for Rage’s nasal therapy to treat inflammatory lung diseases The… Read more »



